In a separate 12-month prospective study of 65 patients with type 2 diabetes mellitus (T2DM) initiating GLP-1 RA therapy (dulaglutide or semaglutide), significant reductions in body weight and BMI were also observed.71 Bone turnover markers and adiponectin levels increased, while myostatin decreased modestly. The gene discussed is GLP1R; the disease is diabetes mellitus.